Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2024-12-04 Legal Proceedings Report
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
소송등의판결ㆍ결정(일정금액이상의청구)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure regarding a court judgment involving a significant claim (damages lawsuit). It details the case name, the court's decision, the financial impact (17.5 billion KRW), and the company's planned legal response. This fits the definition of a Legal Proceedings Report (LTR) as it concerns a significant lawsuit and regulatory/judicial outcome.
2024-12-04 Korean
기타경영사항(자율공시)
Legal Proceedings Report Classification · 100% confidence The document is a formal disclosure regarding a legal proceeding (an appeal of a damages lawsuit). It details the parties involved, the nature of the litigation, and the company's intent to appeal a court decision. This falls under the category of legal proceedings and regulatory disclosures.
2024-12-04 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) regarding a 'Correction Report' (정정신고) for a 'Contract for Stock Collateral Provision involving a Change in the Largest Shareholder'. This type of filing is a standard regulatory disclosure in the Korean market (DART system) concerning financing and capital structure changes. Since it details specific collateral agreements, debt amounts, and changes to existing contracts, it falls under the 'Capital/Financing Update' category.
2024-12-03 Korean
주요사항보고서(신주인수권부사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Supervisory Service (FSS) and the Korea Exchange (KRX) by GemVax & Kael. It details the board's decision to issue private placement bonds with warrants (신주인수권부사채 발행결정). This type of filing is a standard regulatory disclosure in the Korean market regarding capital structure changes and financing activities. Since it specifically details the issuance of new financial instruments (bonds with warrants) to raise capital, it falls under the 'Capital/Financing Update' category.
2024-11-28 Korean
주요사항보고서(신주인수권부사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange, specifically detailing the decision to issue Bond with Warrant (BW) (신주인수권부사채 발행결정). This is a formal regulatory filing regarding capital structure changes and financing activities. It is not a report publication announcement, but the primary disclosure document itself. Therefore, it falls under the 'Capital/Financing Update' category.
2024-11-28 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) regarding a 'Correction Report' (정정신고) for a 'Pledge of Shares' (주식 담보제공 계약). It details the modification of collateral terms for loans taken by the major shareholder. This type of disclosure is a standard regulatory requirement for material changes in share ownership or collateralization, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Major Shareholding Notification' (which is for threshold crossings).
2024-11-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.